Author

L. E. Heasley

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Cancer Biology· 5

Signature Assays, Organisms & Methods

Click to filter · or open tag

Approach:experimental assay· 5 Organism:mouse· 5 Assay:bulk RNA-seq· 3 Research Focus:cancer & tumor microenvironment· 3 Research Focus:host-pathogen & immune response· 2 Research Focus:cell type annotation· 1 Assay:CRISPR screen· 1 Research Focus:drug response / drug discovery· 1

Frequent Co-Authors

R. A. Nemenoff· 5 shared A. T. Le· 4 shared T. K. Hinz· 4 shared A. Navarro· 3 shared E. K. Kleczko· 3 shared E. T. Clambey· 3 shared A. M. Johnson· 2 shared E. L. Schenk· 2 shared

Activity by Year

2020-2023 · peak 3/yr

Co-Author Collaboration Network

10 top collaborators · 40 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

5 shared papersCancer Biology

R. A. Nemenoff

Mutual co-authors in cluster

Author profile →

5 papers

Recent·Most cited

A Rapid, Functional sgRNA Screening Method for Generating Murine RET and NTRK1 Fusion Oncogenes

L. E. Heasley, L. Schubert, A. T. Le, T. K. Hinz, A. Navarro, S. K. Nelson-Taylor, R. A. Nemenoff, R. C. Doebele

This paper describes a method to validate sgRNAs that generate RET and NTRK1 fusion oncogenes in murine models, demonstrating their efficacy in creating tumor models responsive to targeted therapies.

bioRxiv · Apr 6, 2023 · PreprintCancer Biology

Novel EGFR-Mutant Mouse Models of Lung Adenocarcinoma Reveal Adaptive Immunity Requirement for Durable Osimertinib Response

L. E. Heasley, E. K. Kleczko, A. T. Le, T. K. Hinz, T. T. Nguyen, A. Navarro, C.-J. Hu, E. T. Clambey, D. T. Merrick, M. Weiser-Evans, R. A. Nemenoff

bioRxiv · Oct 26, 2022Cancer Biology

Evaluation of KRASG12C Inhibitor Responses in Novel Murine KRASG12C Lung Cancer Cell Line Models

D. J. Sisler, T. K. Hinz, A. T. Le, E. K. Kleczko, R. A. Nemenoff, L. E. Heasley

This paper develops three novel murine KRASG12C-driven lung cancer cell lines to evaluate responses to KRASG12C inhibitors and identify combination strategies for improved therapeutic outcomes.

bioRxiv · Aug 19, 2022Cancer Biology

Adaptive immunity is required for durable responses to alectinib in murine models of EML4-ALK lung cancer

E. K. Kleczko, T. K. Hinz, T. T. Nguyen, N. J. Gurule, A. Navarro, A. T. Le, A. M. Johnson, J. Kwak, D. I. Polhac, E. T. Clambey, M. C. Weiser-Evans, T. Patil, E. L. Schenk, L. E. Heasley, R. A. Nemenoff

This paper shows that adaptive immunity enhances the durability of alectinib response in EML4-ALK lung cancer models, with CD8+ T cells playing a key role.

bioRxiv · Apr 14, 2022 · PreprintCancer Biology

Cancer Cell Intrinsic Expression of MHCII Regulates the Immune Microenvironment and Response to Anti-PD-1 Therapy in Lung Adenocarcinoma

A. M. Johnson, B. L. Bullock, A. J. Neuwelt, J. M. Poczobutt, R. E. Kaspar, H. Y. Li, J. W. Kwak, K. Hopp, M. C. M. Weiser-Evans, L. E. Heasley, E. L. Schenk, E. T. Clambey, R. A. Nemenoff

This study shows that cancer cell expression of MHCII affects T cell infiltration and response to anti-PD-1 therapy in lung adenocarcinoma.

bioRxiv · Jan 9, 2020 · PreprintCancer Biology